News
GSK
48.29
-0.86%
-0.42
GSK: 2026 Looks Good
Seeking Alpha · 7h ago
TD Cowen Remains a Hold on GlaxoSmithKline (GSK)
TipRanks · 13h ago
BUZZ-CAMP4 Therapeutics drops after $30 mln stock sale, GSK deal
Reuters · 15h ago
Camp4 Therapeutics, GSK enter strategic collaboration
TipRanks · 17h ago
CAMP4 THERAPEUTICS - UNDER DEAL WITH GSK, ELIGIBLE FOR UP TO $440 MLN IN MILESTONE PAYMENTS - SEC FILING
Reuters · 17h ago
CAMP4 THERAPEUTICS CORP: UNDER TERMS OF AGREEMENT, CAMP4 WILL RECEIVE $17.5 MLN CASH UPFRONT PAYMENT
Reuters · 17h ago
UPDATE 3-AbbVie, several other pharma companies near MFN deal with Trump, sources say
Reuters · 1d ago
More pharmas expected to sign drug pricing deals with Trump on Friday - report
Seeking Alpha · 1d ago
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
TipRanks · 1d ago
UK’s $49 Billion R&D Plan Puts Quantum Tech on Investors’ Radar
TipRanks · 1d ago
GSK announces FDA approval of Exdensur for severe asthma treatment
TipRanks · 1d ago
GSK wins FDA approval for Exdensur in severe eosinophilic asthma
Seeking Alpha · 1d ago
UK Stocks-Factors to watch on December 17
Reuters · 2d ago
CDC signs off on change in newborn hepatitis b vaccine schedule
Seeking Alpha · 2d ago
FDA Approves GSK’s Exdensur for Severe Eosinophilic Asthma
Reuters · 2d ago
EXDENSUR (DEPEMOKIMAB) APPROVED BY US FDA FOR THE TREATMENT OF SEVERE ASTHMA
Reuters · 2d ago
GSK says FDA approves Exdensur as add-on maintenance treatment
TipRanks · 2d ago
Deutsche Bank Remains a Hold on GlaxoSmithKline (GSK)
TipRanks · 2d ago
UK Stocks-Factors to watch on December 16
Reuters · 3d ago
GSK plc Reports Acquisition of Common Shares in Wave Life Sciences Ltd
Reuters · 3d ago
More
Webull provides a variety of real-time GSK stock news. You can receive the latest news about GSK PLC through multiple platforms. This information may help you make smarter investment decisions.
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.